FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307648839> ?p ?o ?g. }

• W4307648839 endingPage "1098" @default.
• W4307648839 startingPage "1089" @default.
• W4307648839 abstract "Background Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide, and it is associated with a high risk of recurrent stroke with currently recommended treatments. We aimed to evaluate the effect of chronic remote ischaemic conditioning on prevention of ischaemic events in patients with symptomatic ICAS. Methods The RICA trial is a multicentre, randomised, double-blind, sham-controlled trial at 84 stroke centres in China. Patients aged 40–80 years with ischaemic stroke or transient ischaemic attack attributable to angiographically verified 50–99% stenosis of a major intracranial artery were randomly assigned (1:1), via an interactive web-based system by computer-generated randomisation code, to either remote ischaemic conditioning or sham remote ischaemic conditioning once daily for 12 months and voluntarily thereafter. All investigators and patients were masked to treatment allocation. The primary efficacy endpoint was the time to first occurrence of non-fatal or fatal ischaemic stroke, with survival analysed by the Kaplan-Meier method. Primary and safety analyses were done in the intention-to-treat population. The RICA trial is registered with ClinicalTrials.gov, number NCT02534545. Findings Between Oct 28, 2015, and Feb 28, 2019, 3033 patients were enrolled and randomly assigned to either remote ischaemic conditioning (n=1517; intervention group) or sham remote ischaemic conditioning (n=1516; sham group). Median follow-up was 3·5 years (IQR 2·7–4·4). A non-fatal or fatal ischaemic stroke occurred in 257 (16·9%) patients in the intervention group compared with 288 (19·0%) patients in sham group. There was no difference in the survival distribution for time to first occurrence of non-fatal or fatal ischaemic stroke (hazard ratio 0·87, 95% CI 0·74–1·03; p=0·12). In the intervention group, 79 (5·2%) patients died from any cause, and in the sham group, 84 (5·5%) patients died from any cause (hazard ratio 0·93, 95% CI 0·68–1·27; p=0·65). No intervention-related serious adverse events were observed. Interpretation No evidence was found for a difference between remote ischaemic conditioning and sham remote ischaemic conditioning in lowering the risk of ischaemic stroke in patients with symptomatic ICAS. The benefit of remote ischaemic conditioning might have been diluted by poor compliance. Future studies of remote ischaemic conditioning in this population should address challenges in patients’ compliance and assess longer term treatment. Funding Ministry of Science and Technology China, Beijing Municipal Education Commission, Beijing Municipal Finance Bureau. Translation For the Chinese translation of the abstract see Supplementary Materials section. Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide, and it is associated with a high risk of recurrent stroke with currently recommended treatments. We aimed to evaluate the effect of chronic remote ischaemic conditioning on prevention of ischaemic events in patients with symptomatic ICAS. The RICA trial is a multicentre, randomised, double-blind, sham-controlled trial at 84 stroke centres in China. Patients aged 40–80 years with ischaemic stroke or transient ischaemic attack attributable to angiographically verified 50–99% stenosis of a major intracranial artery were randomly assigned (1:1), via an interactive web-based system by computer-generated randomisation code, to either remote ischaemic conditioning or sham remote ischaemic conditioning once daily for 12 months and voluntarily thereafter. All investigators and patients were masked to treatment allocation. The primary efficacy endpoint was the time to first occurrence of non-fatal or fatal ischaemic stroke, with survival analysed by the Kaplan-Meier method. Primary and safety analyses were done in the intention-to-treat population. The RICA trial is registered with ClinicalTrials.gov, number NCT02534545. Between Oct 28, 2015, and Feb 28, 2019, 3033 patients were enrolled and randomly assigned to either remote ischaemic conditioning (n=1517; intervention group) or sham remote ischaemic conditioning (n=1516; sham group). Median follow-up was 3·5 years (IQR 2·7–4·4). A non-fatal or fatal ischaemic stroke occurred in 257 (16·9%) patients in the intervention group compared with 288 (19·0%) patients in sham group. There was no difference in the survival distribution for time to first occurrence of non-fatal or fatal ischaemic stroke (hazard ratio 0·87, 95% CI 0·74–1·03; p=0·12). In the intervention group, 79 (5·2%) patients died from any cause, and in the sham group, 84 (5·5%) patients died from any cause (hazard ratio 0·93, 95% CI 0·68–1·27; p=0·65). No intervention-related serious adverse events were observed. No evidence was found for a difference between remote ischaemic conditioning and sham remote ischaemic conditioning in lowering the risk of ischaemic stroke in patients with symptomatic ICAS. The benefit of remote ischaemic conditioning might have been diluted by poor compliance. Future studies of remote ischaemic conditioning in this population should address challenges in patients’ compliance and assess longer term treatment." @default.
• W4307648839 created "2022-11-04" @default.
• W4307648839 creator A5003261339 @default.
• W4307648839 creator A5004400743 @default.
• W4307648839 creator A5013168917 @default.
• W4307648839 creator A5017774638 @default.
• W4307648839 creator A5021212748 @default.
• W4307648839 creator A5022597730 @default.
• W4307648839 creator A5028789471 @default.
• W4307648839 creator A5030333910 @default.
• W4307648839 creator A5030381944 @default.
• W4307648839 creator A5035259025 @default.
• W4307648839 creator A5036367482 @default.
• W4307648839 creator A5036747513 @default.
• W4307648839 creator A5041731322 @default.
• W4307648839 creator A5043144850 @default.
• W4307648839 creator A5045490940 @default.
• W4307648839 creator A5046796385 @default.
• W4307648839 creator A5049444390 @default.
• W4307648839 creator A5049702998 @default.
• W4307648839 creator A5051528639 @default.
• W4307648839 creator A5053669705 @default.
• W4307648839 creator A5056828509 @default.
• W4307648839 creator A5070578002 @default.
• W4307648839 creator A5070701454 @default.
• W4307648839 creator A5071189943 @default.
• W4307648839 creator A5072162370 @default.
• W4307648839 creator A5080225868 @default.
• W4307648839 creator A5083965647 @default.
• W4307648839 creator A5085282130 @default.
• W4307648839 creator A5090166634 @default.
• W4307648839 creator A5091449910 @default.
• W4307648839 creator A5091896275 @default.
• W4307648839 date "2022-12-01" @default.
• W4307648839 modified "2023-10-17" @default.
• W4307648839 title "Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China" @default.
• W4307648839 cites W2054766445 @default.
• W4307648839 cites W2081859324 @default.
• W4307648839 cites W2103902091 @default.
• W4307648839 cites W2123634131 @default.
• W4307648839 cites W2152601292 @default.
• W4307648839 cites W2167806412 @default.
• W4307648839 cites W2185943660 @default.
• W4307648839 cites W2325867355 @default.
• W4307648839 cites W2332389703 @default.
• W4307648839 cites W2460864360 @default.
• W4307648839 cites W2509312370 @default.
• W4307648839 cites W2527805040 @default.
• W4307648839 cites W2592988020 @default.
• W4307648839 cites W2739907642 @default.
• W4307648839 cites W2741477784 @default.
• W4307648839 cites W2765959279 @default.
• W4307648839 cites W2891602399 @default.
• W4307648839 cites W2922099742 @default.
• W4307648839 cites W2969767078 @default.
• W4307648839 cites W2972010323 @default.
• W4307648839 cites W3013474046 @default.
• W4307648839 cites W3025180722 @default.
• W4307648839 cites W3033909509 @default.
• W4307648839 cites W3164908038 @default.
• W4307648839 cites W3197233575 @default.
• W4307648839 cites W3216605625 @default.
• W4307648839 cites W333169356 @default.
• W4307648839 cites W4221015477 @default.
• W4307648839 cites W4253878427 @default.
• W4307648839 doi "https://doi.org/10.1016/s1474-4422(22)00335-0" @default.
• W4307648839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36354026" @default.
• W4307648839 hasPublicationYear "2022" @default.
• W4307648839 type Work @default.
• W4307648839 citedByCount "14" @default.
• W4307648839 countsByYear W43076488392022 @default.
• W4307648839 countsByYear W43076488392023 @default.
• W4307648839 crossrefType "journal-article" @default.
• W4307648839 hasAuthorship W4307648839A5003261339 @default.
• W4307648839 hasAuthorship W4307648839A5004400743 @default.
• W4307648839 hasAuthorship W4307648839A5013168917 @default.
• W4307648839 hasAuthorship W4307648839A5017774638 @default.
• W4307648839 hasAuthorship W4307648839A5021212748 @default.
• W4307648839 hasAuthorship W4307648839A5022597730 @default.
• W4307648839 hasAuthorship W4307648839A5028789471 @default.
• W4307648839 hasAuthorship W4307648839A5030333910 @default.
• W4307648839 hasAuthorship W4307648839A5030381944 @default.
• W4307648839 hasAuthorship W4307648839A5035259025 @default.
• W4307648839 hasAuthorship W4307648839A5036367482 @default.
• W4307648839 hasAuthorship W4307648839A5036747513 @default.
• W4307648839 hasAuthorship W4307648839A5041731322 @default.
• W4307648839 hasAuthorship W4307648839A5043144850 @default.
• W4307648839 hasAuthorship W4307648839A5045490940 @default.
• W4307648839 hasAuthorship W4307648839A5046796385 @default.
• W4307648839 hasAuthorship W4307648839A5049444390 @default.
• W4307648839 hasAuthorship W4307648839A5049702998 @default.
• W4307648839 hasAuthorship W4307648839A5051528639 @default.
• W4307648839 hasAuthorship W4307648839A5053669705 @default.
• W4307648839 hasAuthorship W4307648839A5056828509 @default.
• W4307648839 hasAuthorship W4307648839A5070578002 @default.
• W4307648839 hasAuthorship W4307648839A5070701454 @default.
• W4307648839 hasAuthorship W4307648839A5071189943 @default.
• W4307648839 hasAuthorship W4307648839A5072162370 @default.

• next